31 C
Vientiane
Saturday, April 26, 2025
spot_img
Home Blog Page 498

100MW/331MWh Bramley Energy Storage Project in the UK Now Operational, Thanks to BW ESS and Sungrow

  • BW ESS and Sungrow celebrate the successful commercial operation of the 100MW/331MWh Bramley battery energy storage system (BESS), a milestone in strengthening UK energy security.
  • Featuring Sungrow’s PowerTitan 2.0, the project benefits from cutting-edge grid-forming technology, enhanced safety features, and optimized cost efficiency, ensuring long-term performance.

LONDON, Feb. 19, 2025 /PRNewswire/ — BW ESS and Sungrow are pleased to announce the commercial operation of the 100MW/331MWh Bramley battery energy storage system (BESS). The commercial operation ceremony that took place on site on Monday, February 17th, marked this significant milestone for the project.

100MW/331MWh Bramley Energy Storage Project in the UK Now Operational, Thanks to BW ESS and Sungrow
100MW/331MWh Bramley Energy Storage Project in the UK Now Operational, Thanks to BW ESS and Sungrow

Installed with Sungrow’s cutting-edge BESS 3-hour PowerTitan 2.0, the Bramley project will play a vital role in bolstering UK energy security and fortifying the resilience of the electricity system. The project is connected to the UK grid 132kV electric circuit by the loop-in and loop-out Extra High Voltage (EHV) solution, optimising line protection and power generation protection schemes. The grid-forming technologies of PowerTitan 2.0 help tackle the power grid challenges of decreasing inertia and damping due to the increasing penetration of renewable energy sources.

In addition, the PowerTitan 2.0’s pioneering technology significantly reduces both capital expenditure (CAPEX) and operational expenditure (OPEX) costs. The all-in-one AC-DC block design of PowerTitan 2.0, with pre-assembled battery modules and PCS, ensures seamless integration, significantly reducing installation time. With PowerTitan 2.0, the project complies with the UK electricity market codes and actively participates in grid balancing, ancillary services, and wholesale energy trading, ensuring competitive benefits for stakeholders.

As safety is the priority of energy storage systems, Sungrow conducted the world’s largest BESS burn test for the PowerTitan 2.0, enabling exceptional safety for plants including the Bramley project.

“This is a landmark moment for BW ESS’ UK roll-out, and a notable project in the context of the UK’s energy transition,” said Erik Strømsø, CEO of BW ESS. “Bramley is a state-of-the-art, pioneering project aligned with our mission to unlock the value of energy storage. I’m grateful that so many of our peers and partners were able to join us to mark the occasion.”

Shawn Shi, President of Sungrow Europe, commented: “We are proud to partner with BW ESS on this groundbreaking project. The Bramley BESS exemplifies our commitment to advancing clean energy solutions that not only support grid stability but also contribute to a more resilient and sustainable energy future. With the PowerTitan 2.0, we are setting new standards for efficiency, safety, and scalability, ensuring that we continue to meet the evolving energy needs of the UK and beyond.”

The partnership between Sungrow and BW ESS continues to grow. Last September, Sungrow further solidified its collaboration with BW ESS, signing an agreement for a 1.4GWh PowerTitan 2.0 ESS to support the development of the Hams Hall energy storage project in the UK.

About Sungrow

Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 28 years. As of December 2024, Sungrow has installed 740 GW of power electronic converters worldwide. The Company is recognized as the world’s No. 1 on PV inverter shipments (S&P Global Commodity Insights) and the world’s most bankable energy storage company (BloombergNEF). Its innovations power clean energy projects in over 180 countries, supported by a network of 520 service outlets guaranteeing excellent customer experience. At Sungrow, we’re committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com.

CONTACT: Mina Zhang, mina.zhang@cn.sungrowpower.com 

Altair Releases Altair® HyperWorks® 2025

New capabilities and enhancements make a zero-prototype world possible

TROY, Mich., Feb. 19, 2025 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational intelligence, is thrilled to announce the release of Altair® HyperWorks® 2025, a best-in-class design and simulation platform for solving the world’s most complex engineering challenges. At the forefront of this release is a bold vision of the future of product development: a zero-prototype world, where design is perfected in the virtual domain before reaching the physical world. By combining the power of artificial intelligence (AI), high-performance computing (HPC), and multiphysics simulation with cloud-based scalability and digital thread connectivity, Altair HyperWorks 2025 is more than a simulation platform – it’s a launchpad for innovation.

Altair has announced Altair® HyperWorks® 2025, the latest evolution of its simulation and design platform.
Altair has announced Altair® HyperWorks® 2025, the latest evolution of its simulation and design platform.

“Altair HyperWorks 2025 builds on four decades of Altair’s expertise in simulation, design, and optimization,” said James R. Scapa, founder and chief executive officer, Altair. “By integrating advanced simulation technologies with AI and machine learning, automation, open architecture, and a connected digital thread, the platform accelerates design processes, fosters scalable cloud collaboration, and empowers teams to deliver smarter, faster, and more sustainable solutions. It is yet another leap in our vision of democratized computational intelligence.”

AI-Powered Engineering and Optimization

Altair continues to pull away from the competition with our unparalleled AI-powered engineering, machine learning, and optimization capabilities. Physics prediction models powered by new transformer architectures deliver accurate simulations, even with limited or incomplete data. Machine learning models act as solvers, slashing simulation times while improving reliability. AI-enabled reduced order modeling (ROM) enables faster, more precise simulations of nonlinear systems, providing insights early in the design process.

Cloud-Based and SaaS Solutions

Embracing the shift to cloud-based and SaaS solutions, Altair is democratizing access to advanced engineering simulations with flexible infrastructure. The new Altair® DSim™ SaaS solution allows semiconductor designers to run unlimited simulations with a pay-as-you-go model, eliminating upfront costs and offering the freedom to scale on demand. And the Altair One® cloud innovation gateway enhances collaboration, providing instant access to simulation applications, data, and HPC resources.

Automation and Customization

New automation capabilities, including Python APIs, eliminate repetitive tasks, streamline data queries, and simplify report generation. For large-scale projects, advanced batch execution and task libraries reduce time spent on complex workflows. The platform’s customization options allow users to tailor simulations to unique applications, such as modeling particle interactions in pharmaceuticals or agriculture.

Additional Highlights

Digital Engineering: A Connected Ecosystem

By connecting data, teams, and processes across the product life cycle, Altair delivers a more integrated approach to design and simulation. Enhanced digital twin and digital thread technologies ensure seamless data flow and align virtual models with physical systems. To meet sustainability goals, private material databases provide a single source of truth for material decisions, including tools for carbon dioxide (CO₂) impact analysis.

Solver Efficiency

Simplifying structural simulations, the “One Model, One Solver” approach of Altair® OptiStruct® enables smooth transitions between implicit and explicit analyses. By deploying Altair® PhysicsAI™ models as solvers, users can replace traditional numerical solvers with AI-powered alternatives, accelerating simulations while maintaining accuracy.

Multiphysics Simulation for Electronics

Recent updates simplify managing thermal, electromagnetic, and power interactions in electronics design. ECAD meshing improvements speed up cooling and durability analysis, while enhanced electromagnetic-thermal coupling provides better system performance predictions. Power electronics simulation updates optimize motor drive and converter modeling for improved efficiency.

CAE as a Design Tool

Altair® Inspire™ continues to make CAE essential by offering designer-friendly computational physics for structural, fluid, and motion analysis – alongside manufacturability and optimization workflows. Altair® CoPilot™ Beta – an intelligent AI-assistant embedded within Inspire – provides on-demand guidance, Q&A, and workflow support, while new tools like image planes for sketching and expanded implicit modeling streamline geometry creation and exploration.

Advanced Material Simulation

As material complexity, sustainability demands, and AI-powered workflows advance, Altair’s material solutions give users the tools they need to lead. With Altair’s material solutions, organizations can source, standardize, and simulate high-fidelity material data for advanced materials like composites, polymers, and additive manufacturing. Engineers can optimize designs, achieve sustainability goals with CO₂ analysis, and reduce physical testing costs by using AI to complete missing data.

Particle Simulation

Altair continues to define the industry standard for the discrete element method (DEM) by delivering new physics models—a Fibers Bonding Model, Liquid Bridge Model, and updated Linear Elastic Bond Model (LEBM) with polyhedral particles—enhance workflows and enable a realistic representation of fibers and particles for applications in agriculture, batteries, and pharmaceuticals.

To learn more about Altair HyperWorks and see the full list of enhancements, visit https://altair.com/hyperworks-2025.

About Altair

Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. To learn more, please visit www.altair.com.

Media contacts               

Altair Corporate                       

Altair Investor Relations

Bridget Hagan                           

Stephen Palmtag

+1.216.769.2658                       

+1.669.328.9111

corp-newsroom@altair.com       

ir@altair.com

Altair Europe/The Middle East/Africa   

Altair Asia-Pacific

Louise Wilce                                         

Man Wang

+44 (0)7392 437 635

86-21-5016635,,825

emea-newsroom@altair.com               

apac-newsroom@altair.com

 

 

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

–  ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg).
–  ASC30 oral once-daily tablet also demonstrated a 4.3% mean body weight reduction from baseline after 28-day treatment in MAD cohort 1 (weekly titrations of 2 mg, 5 mg, 10 mg, and 20 mg).
–  0.1% mean body weight reduction from baseline was observed after 28-day treatment with matching placebo tablets.

HONG KONG, Feb. 19, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces today positive interim results from the first two cohorts of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in patients with obesity (body mass index (BMI): 30-40 kg/m2). The Phase Ib MAD study consists of 3 cohorts, with eight patients in each cohort on ASC30 tablets and two patients in each cohort on matching placebo. Cohort 1 had four dose levels (2 mg, 5 mg, 10 mg, and 20 mg). Patients in cohort 1 received each dose level of ASC30 or placebo for seven days in a sequential manner. The average daily dose over the 28-day treatment period was 9.25 mg ASC30 for cohort 1. Cohort 2 had four dose levels (2 mg, 10 mg, 20 mg, and 40 mg). Patients in cohort 2 received each dose level of ASC30 or placebo for seven days in a sequential manner. The average daily dose over the 28-day treatment period was 18 mg ASC30 for cohort 2.

Mean body weight reductions from baselines were 4.3% and 6.3% for MAD cohorts 1 and 2, respectively, after 28-day treatment with ASC30 oral once-daily tablets. Placebo-adjusted mean body weight reductions from baselines were 4.2% and 6.2% for MAD cohorts 1 and 2, respectively.

ASC30 was generally well tolerated in MAD cohorts 1 and 2, with a favorable safety profile. There were no serious adverse events (SAEs). All gastrointestinal (GI)-related adverse events (AEs) were mild (grade 1) or moderate (grade 2). Weekly titrations of ASC30 improved GI tolerability. In MAD cohort 1, there were no incidences of vomiting. No clinically significant changes in liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBL) were observed. There were no clinically significant findings in laboratory tests, vital signs, ECGs (electrocardiograms, including QTc intervals), and physical exams.

Detailed results will be presented at a future medical conference.

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1 receptor (GLP-1R) biased agonist designed to be dosed once daily orally and once monthly subcutaneously for the treatment of obesity.

“We are excited that these interim results from our Phase Ib MAD study demonstrated potential best-in-class characteristics to treat patients with obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “As a small molecule, ASC30 has the potential to offer both once-daily oral and once-monthly subcutaneous injection dosing options for patients, if approved.”

In January 2025, Ascletis announced positive topline results from its U.S. single ascending dose (SAD) study (NCT06680440) of ASC30 oral tablet in patients with obesity (BMI: 30-40 kg/m2) (Link). The SAD study consisted of five cohorts (2 mg, 5 mg, 10 mg, 20 mg, and 40 mg) with a total of 40 patients with obesity under fasting conditions.

ASC30 Oral Tablet U.S. Phase Ib MAD Study Update

The ASC30 oral tablet MAD study is designed as a randomized, double-blind, placebo-controlled study consisting of three cohorts. Patients with obesity receive either ASC30 oral tablet or matching placebo once daily for 28 days, with weekly titrations. Cohort 1 (2 mg, 5 mg, 10 mg, and 20 mg) and cohort 2 (2 mg, 10 mg, 20 mg, and 40 mg) have been completed. Cohort 3 (5 mg, 15 mg, 30 mg, and 60 mg) is expected to be completed by the end of March 2025, and topline results will be available soon after.

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. 

About Ascletis Pharma Inc.

Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline.

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion

–       Dr. Terence Kelly named interim CEO and Prof. Damian O’Connell named Chair of the Scientific Advisory Board, joins Board of Directors
–       Appointment of US-based CEO completes the recent build out of BluMaiden’s executive team in preparation for commercialization, supported by COO Dr. Damien Keogh and CFO Kenneth Ling
–       BluMaiden’s differentiated AI drug discovery approach bridges the gap with natural substances and has already yielded three inflammatory disease targets that are being advanced to pre-clinical models

SINGAPORE, Feb. 19, 2025 /PRNewswire/ — BluMaiden Biosciences (“BluMaiden”), an AI drug discovery company pioneering a proprietary reverse translation approach that enables target and natural product bases drug candidate selection, announced the appointment of Dr. Terence Kelly as interim Chief Executive Officer and Professor Damian O’Connell as Chair of the Science Advisory Board and member of the Board of Directors. Dr. Damien Keogh, founder of BluMaiden, will assume the role of Chief Operations Officer, focused on driving the company’s scientific, technical, business development, and corporate functions.

“As BluMaiden enters the exciting phase of scaling operations in the US, advancing its first targets to pre-clinical models, and expanding commercial partnerships to accelerate the development of more effective therapeutics, we are pleased to welcome Terry and Damian in their new roles. Their breadth of experience in global drug discovery, clinical development leadership, and commercial strategy will bring important insights to the team,” commented Michael Tillman, Chairman of BluMaiden. “Following the recent appointment of Kenneth Lim as CFO and Damien spearheading operations, BluMaiden now has a full executive team in place to drive growth and execute on its commercial strategy.”

“Damien and the team have rapidly established BluMaiden at the forefront of innovative AI drug discovery, integrating advanced technology and scientific rigor to identify safer, biocompatible small molecule drug candidates from within the human body. I am looking forward to leading the team to scale commercial partnerships that deliver a transformative approach to drug discovery,” said Dr. Kelly. “My experience has taught me the difficulties faced in developing new treatments to address challenging therapeutic areas and I’m impressed by the progress that BluMaiden is already making in the fields of inflammatory disease and oncology.”

Professor O’Connell added, “As Chair of the Scientific Advisory Board and Board Member, I am excited to contribute my knowledge and experience to support BluMaiden’s growth. The intersection of AI and drug discovery holds incredible potential and BluMaiden’s differentiated approach is generating some fascinating insights into how human-derived natural product data can yield disease mechanism insights leading to the discovery of next-generation small molecule therapeutics.”

Dr. Kelly brings 35 years of drug discovery and development experience. He previously led Boehringer Ingelheim’s US medicinal chemistry department and was chief executive officer of CoMentis and Perception Neuroscience, US-based clinical-stage biotech companies focused on neurodegeneration and psychiatric disease. Dr. Kelly joined the Board of BluMaiden as a non-executive director in 2021. Throughout his career, he has led teams in medicinal chemistry, high throughput screening, computational chemistry, structural biology, and combinatorial chemistry.  Dr. Kelly is based in the US and will support the company to build commercial and scientific teams there.

Professor O’Connell has over 25 years’ experience in pharma leadership, including roles as SVP and Global Head of Clinical Sciences at Bayer Pharma AG, as well as senior positions at Pfizer, Parke Davis, and Elan Pharmaceuticals. He is currently CEO of the Experimental Drug Development Centre, Singapore’s national platform for drug discovery and development, and holds additional positions including Adjunct Professor at the University College Cork, Ireland. Prof. O’Connell will join the Board of BluMaiden as a non-executive director.

BluMaiden Biosciences harnesses naturally occurring human-derived small molecules to develop superior therapeutics. The company’s advanced computational platform explores previously untapped chemical space within the human body, identifying safer, biocompatible small molecule drug candidates. By overcoming the limitations of synthetic chemistry that often lead to revenue loss, high clinical development costs, and trial failures, BluMaiden enables its pharma partners to bring better drugs to market faster. Integrating advanced AI-guided computational chemistry with genetics and disease mechanism insights from human clinical trial data, BluMaiden is at the forefront of next-generation small molecule therapeutics, driving innovation to transform patient outcomes. Using its proprietary approach, BluMaiden has identified three inflammatory disease targets that it is advancing to pre-clinical models.

Ends

About BluMaiden Biosciences

BluMaiden Biosciences is a Singapore-headquartered biotech firm that is operational in the USA and Europe. It is a data-driven innovator producing actionable clinical insights to enhance clinical trial decision-making, commercialized through its Pharma Service. The company also identifies licensable small molecule drugs through its flagship platform MAIDENTM, that couples computational biology with computational chemistry to mine human clinical data for novel therapeutics. BluMaiden Biosciences has established strategic partnerships with AWS (certified Qualified Software Partner) and a growing network of healthcare and life science companies in the US and Europe. For more information please visit BluMaiden.com 

 

 

Hisense Laser TV Maintains Global No.1 Position for Six Years

QINGDAO, China, Feb. 19, 2025 /PRNewswire/ — Hisense, a global leader in consumer electronics and home appliances, is once again demonstrating its dominance by securing the top position globally in Laser TV. According to data from the international market research institute Omdia, Hisense’s laser TV achieved a 65.8% global market share in 2024, meaning that for every three laser TVs sold, nearly two are from Hisense. This also marks six consecutive years as the world’s leading Laser TV shipment provider.

Hisense Laser TV ranked global No. 1
Hisense Laser TV ranked global No. 1

As one of the earliest entrants in the laser display market, Hisense has evolved its offerings — from single-color to triple-color laser systems, from 4K to 8K resolution, and from rollable to foldable screens — solidifying its leadership in the ultra-large screen TV segment. In 2024, Hisense recorded triple-digit year-on-year growth in key markets such as the UK, Italy, Spain, and Poland, while also posting increases of over 70% in France, Australia, and Germany.

Further establishing its leadership in the laser display industry, the Hisense PX3-PRO TriChroma Laser Projector secured the top spot at the 2024 Prestigious Projector Showdown. This prestigious event, which evaluates ultra short throw (UST) projectors, recognized the PX3-PRO for its superior performance in color accuracy, contrast, and sharpness, solidifying Hisense’s position as a pioneer in the field. With groundbreaking features like a 3,000:1 native contrast ratio, 3,000 ANSI lumens brightness, and TriChroma™ triple laser technology, the PX3-PRO sets new standards in home entertainment.

Hisense’s Laser TV leads in eye care with TÜV Rheinland Low Blue Light and Flicker-Free certifications, while its Laser TV PL1 earns ISO 14067 carbon footprint verification by TÜV Rheinland.

Hisense’s relentless commitment to innovation and quality not only sustains its global leadership but also drives industry standards in ultra-large screen technology. With breakthrough advancements and impressive international growth, Hisense is poised to remain a dominant force in the evolving world of home entertainment.

About Hisense

Hisense is a leading global home appliance and consumer electronics brand. According to Omdia, Hisense has ranked No. 2 globally in total TV shipments from 2022 to 2024, and No. 1 in 100”+ TVs segment from 2023 to 2024. The company has rapidly expanded to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.

Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US

NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ — Biosion, Inc. (“Biosion”), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biotech R&D, clinical and regulatory development, Dr. Lin will play a pivotal role in advancing Biosion’s innovative therapies and strategic initiatives as the company continues its “discover-development-partnership” model.

Dr. Lin also has extensive experience in clinical operation, portfolio management, and business development. Previously, she served as Senior Vice President of U.S. Operations and Corporate Strategy at Harbour Biomed US, where she led successful global clinical development programs and played a key role in business development and alliance management.

“We are thrilled to welcome Kedan to our executive team,” said Dr. Mingjiu Chen, Founder and CEO of Biosion. “Her deep expertise in biologics development and strategic alliances will be instrumental in advancing our mission and delivering breakthrough antibody-based therapies to patients globally. Her appointment is a key step in furthering Biosion’s “In Global for Global” strategy and expanding our global footprint.”

Dr. Lin holds a Ph.D. in Molecular Pharmacology from the University of California, San Francisco, and has held leadership roles at Innovent Biologics, NGM Biopharmaceuticals, and Genentech. A recognized expert in translational development for antibody therapeutics, she has contributed extensively to the scientific community.

“I am excited to join the Biosion team at this pivotal time,” said Dr. Lin. “I look forward to working alongside the talented team at Biosion to continue advancing innovative therapies that address unmet medical needs, all while strengthening our global impact and helping patients worldwide.”

For more information on Biosion’s clinical programs and pipeline, visit www.biosion.com.

About Biosion

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies including the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide. With its “discover-development-partnership” model, the company has forged 10 global collaborations, advancing seven clinical-stage assets, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Biosion operates across the US, China, and Australia. Learn more at www.Biosion.com.

Infineon teams up with Thailand Science Research and Innovation to drive innovation ecosystem in Thailand

–  Infineon and Thailand Science Research and Innovation (TSRI) have signed an MoU to strengthen the semiconductor ecosystem in Thailand
–  Collaboration with local entrepreneurs and academic institutions aims at driving innovative products and solutions
–  The agreement covers the development of a secure and scalable AIoT platform to support cybersecurity certifications

BANGKOK, Feb. 19, 2025 /PRNewswire/ — Infineon Technologies Asia Pacific Pte Ltd and Thailand Science Research and Innovation (TSRI), a Thai government agency, have signed a Memorandum of Understanding (MoU) to collaborate in driving growth, innovation and entrepreneurship in Thailand. The focus of this collaboration is on Artificial Intelligence (AI), the Internet of Things (IoT) and other emerging technologies driven by the semiconductor industry.

Infineon and TSRI will jointly promote the development of an ecosystem for startups and small and medium-sized enterprises (SMEs) in Thailand that have the potential to leverage Infineon’s semiconductor technology in the development of innovative products and solutions. The two parties will also work together on upskilling the workforce and fostering talents for the local semiconductor industry. To this end, they plan to encourage research, education and training programs related to semiconductor products at academic institutions.

“We are excited to partner with TSRI in advancing AI and IoT innovation in Thailand,” said Chua Chee Seong, President and Managing Director of Infineon Technologies Asia Pacific Pte Ltd. “This collaboration will enable us to support the growth of startups and SMEs in Thailand and to help develop a robust and cyber-resilient digital economy in the country, further driving decarbonization and digitalization.”

As part of the collaboration, the parties will develop a secure and scalable Artificial Intelligence of Things (AIoT) platform, encompassing frameworks for AIoT Edge, IoT device security, firmware and middleware to support domestic and global cybersecurity certifications, data services and advanced product innovation.

“We are dedicated to increasing funding for research initiatives within higher education institutions to foster innovation and meet the challenges of the future,” said Prof. Dr. Supachai Pathumnakul, Permanent Secretary of the Ministry of Higher Education, Science, Research and Innovation. “We aim to enhance our educational standards and research capabilities through collaboration with global institutions like Infineon. Prioritizing science, technology, engineering and mathematics (STEM) education will empower our students with the skills needed for success in the competitive landscape of tomorrow.”

Infineon recently broke ground for a new semiconductor backend production site in Samut Prakan, south of Bangkok, optimizing and further diversifying its manufacturing footprint.

About Thailand Science Research and Innovation (TSRI)

Thailand Science Research and Innovation (TSRI), a key government organization under Thailand’s Ministry of Higher Education, Science, Research and Innovation, drives national progress by advancing research and innovation. Established under the Industry 4.0 economic model, to expand its role in fostering science, technology, and interdisciplinary collaboration, it funds critical projects in agriculture, healthcare, sustainability, and digital transformation while bridging academia, industry, and policymakers to turn research into real-world solutions. Aligned with national strategies, TSRI strengthens Thailand’s global competitiveness and sustainable development goals, supporting the transition to a high-income, innovation-driven economy through strategic partnerships and international cooperation.

About Infineon

Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The company has around 58,060 employees worldwide and generated revenue of about €15 billion in the 2024 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY).

Picture is available at AP 

Further information is available at www.infineon.com

This press release is available online at www.infineon.com/press

Follow us: X – Facebook – LinkedIn

Press Contact:

Veronika Seifried
+49 89 234 61662
veronika.seifried@infineon.com 

 

LexisNexis Risk Solutions Completes IDVerse Acquisition

Acquisition expands LexisNexis Risk Solutions’ capabilities in risk and fraud solutions and enhances digital identity onboarding and identity verification through AI-powered technology

ATLANTA and LONDON, Feb. 19, 2025 /PRNewswire/ — LexisNexis® Risk Solutions, part of RELX, closed its acquisition of IDVerse™, a provider of AI-powered document authentication and fraud detection solutions. IDVerse is now part of the Business Services segment of LexisNexis Risk Solutions and will continue to be available within its LexisNexis® RiskNarrative® platform, LexisNexis® IDU®, and will be offered within its LexisNexis® Dynamic Decision Platform® as a stand-alone solution later this year. 

Founded in Australia and launched commercially in 2018, IDVerse uses AI to combat fraud and deepfakes. Its proprietary technology is powered by a deep neural network which verifies the authenticity of identity documents and, with consumer consent, matches the consumer’s face to the photo on a document using biometric algorithms for identity verification and liveness detection to detect a fraudulent submission. IDVerse’s technology is capable of verifying more than 16,000 types of identity documents globally across organisations in various industries and the public sector. 

Once integration is complete, LexisNexis Risk Solutions will offer clients even more robust risk insights to better protect consumers, promote financial inclusion for trusted individuals and help organisations globally maintain an optimal risk posture. 

Combining LexisNexis Risk Solutions’ multi-layered identity verification tools with IDVerse’s complementary AI-powered technology will address both evolving customer needs and emerging threats. Expanding global ID verification capabilities will bolster defences against AI-generated fraud, while IDVerse’s self-learning AI will ensure advanced fraud detection, faster fraud model updates and even more accurate identity verification. 

Rick Trainor, CEO of Business Services at LexisNexis Risk Solutions, stated, “Anti-fraud capabilities need to advance as fast or faster than fraudsters innovate their tactics. AI-powered solutions are critical in defending against fraud, particularly AI-generated fraud such as deepfakes. IDVerse’s accelerated innovation in this field is impressive, and I’m eager to see how our complementary cutting-edge solutions will combine to take our anti-fraud capabilities to new levels.” 

The terms of the transaction have not been disclosed. 

About LexisNexis Risk Solutions

LexisNexis® Risk Solutions harnesses the power of data, sophisticated analytics platforms and technology solutions to provide insights that help businesses across multiple industries and governmental entities reduce risk and improve decisions to benefit people around the globe. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of information-based analytics and decision tools for professional and business customers. For more information, please visit LexisNexis Risk Solutions and RELX.

About RELX

RELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 36,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York stock exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £69bn/€82bn/$89bn.

About IDVerse

IDVerse provides tools and infrastructure that help empower the identity verification industry, enabling businesses to verify anyone’s identity within seconds using only their face and smartphone. IDVerse harnesses the power of regenerative AI to not only fight fraud and deepfakes but also significantly reduce associated risks. IDVerse is trusted by financial institutions, fintech, the public sector and global enterprises with offices in Sydney, Melbourne, London and Silicon Valley.

Media Contacts:
LexisNexis Risk Solutions
Ade O’Connor
+44 78 9091 8264
Ade.O’Connor@lexisnexisrisk.com